Evaluation of the Care Provided to Patients Who Underwent Bariatric Surgery and Were Lost to Follow-up 5 Years After Surgery

NCT ID: NCT07118540

Last Updated: 2025-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

176 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2025-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2025, bariatric surgery combined with nutritional and psychological support is one of the most effective treatments for patients with morbid obesity. (2)(3)

However, it causes various deficiencies, such as vitamin and iron deficiencies, which justify lifelong personalised vitamin supplementation and, consequently, lifelong medical supervision. The latest recommendations from the French National Authority for Health (Haute Autorité de Santé) clearly state that patients must commit to lifelong medical follow-up after bariatric surgery. (HAS, February 2024, R94). R94. Regular biological monitoring after bariatric surgery is recommended: three times in the first year and then once or twice a year thereafter.

Within the OBESEPI cohort (clinical trial number NCT02663388), which comprises patients who underwent surgery at Nancy University Hospital between 2013 and 2018, we observed that over 50% of patients were lost to follow-up five years after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Duration of the inclusion period: 3 months Duration of subject participation (from inclusion to the last visit for the same subject): 30 minutes (time required to complete the questionnaire) Total duration of the research: 9 months

Patients with obesity who met the HAS (French high health authority) criteria for surgical treatment were recruited.

This corresponds to patients with a BMI \> 35 kg/m2 with obesity-related complications (hypertension and/or diabetes and/or dyslipidemia and/or obstructive apnea syndrom ) and patients with a BMI \> 40 with or without obesity-related complications.

These patients, who were candidates for scheduled bariatric surgery, were recruited by a surgeon involved in the protocol during preoperative consultations in the Metabolic, Visceral and oncologic department of surgery ; Department at Nancy University Hospital; between 2013 and 2018 (the OBESEPI-ALDEPI cohort - clinical trial NCT02663388) ). All patients met the HAS's eligibility criteria previously cited for bariatric surgery.

Two groups could be studied:

Patients who underwent surgery and were lost to follow-up five years after after bariatric surgery

The second group comprised patients who underwent surgery and were still being monitored at Nancy University Hospital five years after their inclusion.

Patients were considered lost to follow-up if there was no record of them visiting the Metabolic, Visceral and oncologic department of surgery five years after their inclusion, as determined using the DXCare software (which contain medical file).

A questionnaire is used to collect all data. This is completed by telephone or sent by email to patients who have been lost to follow-up.

This questionnaire contains questions designed to help us achieve the main and secondary objectives described in the dedicated section.

Statistical analysis :

All data will be presented as numbers and percentages for qualitative variables, and as means, standard deviations, medians, quartiles, and extreme values for quantitative variables.

The characteristics of patients lost to follow-up from the OBESPI cohort will be compared with those still being followed up using Fisher's exact test, Chi-squared test or Wilcoxon's rank sum test.

To meet the objectives, these tests will also be used to compare patients lost to follow-up with those still being followed.

Assessment of research benefits:

Methods for monitoring patients lost to follow-up should be assessed in order to develop training for general practitioners in the Lorraine region, enabling them to provide appropriate follow-up care to patients who have undergone bariatric surgery.

Train general practitioners to prevent nutritional complications of bariatric surgery.

Train general practitioners to recognise the warning signs that require referral to a specialist centre.

There is major interest in improving healthcare practices, given that 60,000 bariatric surgeries are performed annually in France, with 800,000 patients having undergone surgery in 2019.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity &Amp; Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> Patients included in the OBESEPI cohort;

* Individuals who have received complete information about the organisation of the research and have not objected to their participation and the use of their data;
* Affiliation with a social security scheme.

Exclusion Criteria

* \>Patient who objects to participating in this research;

* Pregnant and breastfeeding women;
* Patients under legal guardianship or curatorship;
* Patients deprived of their liberty by a judicial or administrative decision.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

NOMINE-CRIQUI Claire

Staff surgeon in Visceral Metabolic and oncologic surgery department, head of the endocrine surgery Unit

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire de Nancy

Nancy, Lorraine, France

Site Status ENROLLING_BY_INVITATION

Centre Hospitalier Universitaire de Nancy

Nancy, Lorraine, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Claire NOMINE-CRIQUI, MD

Role: CONTACT

+33632149814

References

Explore related publications, articles, or registry entries linked to this study.

(1)Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 Lancet. 2025 Mar 8; (2)Peirson L, Douketis J, Ciliska D, Fitzpatrick-Lewis D, Ali MU, Raina P. Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. CMAJ Open. Oct 2014;2(4):E306-317. (3)Jackson VM, Breen DM, Fortin JP, et al. Latest approaches for the treatment of obesity. Expert opinion on drug discovery. 2015;10(8):825-839. (4)Recommandation HAS février 2024 : Prise en charge de l'obésité de niveau 2 et 3 https://www.has-sante.fr/upload/docs/application/pdf/2024-02/reco369_recommandations_obesite_2e_3e_niveaux_ii_cd_2024_02_08_preparation_mel.pdf (5)Chirurgie bariatrique : état des lieux en France en 2019 Halimi et al Médecine des maladies Métaboliques

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16062025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.